N Bonnet, L Bourgoin, E Biver,
E Douni… - The Journal of …, 2023 - Am Soc Clin Investig
Receptor activator of NF-κB ligand (RANKL) activates, while osteoprotegerin (OPG) inhibits,
osteoclastogenesis. A neutralizing Ab against RANKL, denosumab, improves bone strength …